CN111588038A - 一种海藻酵素益生菌微胶囊及其制备方法 - Google Patents
一种海藻酵素益生菌微胶囊及其制备方法 Download PDFInfo
- Publication number
- CN111588038A CN111588038A CN202010393045.5A CN202010393045A CN111588038A CN 111588038 A CN111588038 A CN 111588038A CN 202010393045 A CN202010393045 A CN 202010393045A CN 111588038 A CN111588038 A CN 111588038A
- Authority
- CN
- China
- Prior art keywords
- ferment
- microcapsule
- seaweed
- probiotic
- core material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 118
- 239000006041 probiotic Substances 0.000 title claims abstract description 109
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 109
- 241001474374 Blennius Species 0.000 title claims abstract description 79
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 56
- 102000004190 Enzymes Human genes 0.000 title claims description 28
- 108090000790 Enzymes Proteins 0.000 title claims description 28
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000011162 core material Substances 0.000 claims description 60
- 239000007788 liquid Substances 0.000 claims description 58
- 229920001661 Chitosan Polymers 0.000 claims description 47
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 46
- 239000000499 gel Substances 0.000 claims description 22
- 239000011259 mixed solution Substances 0.000 claims description 21
- 239000000661 sodium alginate Substances 0.000 claims description 21
- 229940005550 sodium alginate Drugs 0.000 claims description 21
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 20
- 235000010413 sodium alginate Nutrition 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 15
- 229920002261 Corn starch Polymers 0.000 claims description 15
- 239000008120 corn starch Substances 0.000 claims description 15
- 241000199919 Phaeophyceae Species 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 241000195628 Chlorophyta Species 0.000 claims description 13
- 241000206572 Rhodophyta Species 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 239000001110 calcium chloride Substances 0.000 claims description 12
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 11
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 9
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 9
- 241000196252 Ulva Species 0.000 claims description 9
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 8
- 238000007664 blowing Methods 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 238000005538 encapsulation Methods 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 238000009630 liquid culture Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241001261506 Undaria pinnatifida Species 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 229960000583 acetic acid Drugs 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 239000012362 glacial acetic acid Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 4
- 241000193171 Clostridium butyricum Species 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000006641 stabilisation Effects 0.000 claims description 4
- 238000011105 stabilization Methods 0.000 claims description 4
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- 244000003416 Asparagus officinalis Species 0.000 claims description 3
- 235000005340 Asparagus officinalis Nutrition 0.000 claims description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- 241000206575 Chondrus crispus Species 0.000 claims description 3
- 241001428166 Eucheuma Species 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 3
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 3
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 3
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 3
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 241000206607 Porphyra umbilicalis Species 0.000 claims description 3
- 241000264279 Sargassum fusiforme Species 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000015278 beef Nutrition 0.000 claims description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 3
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 claims description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000005429 filling process Methods 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 3
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 229940087562 sodium acetate trihydrate Drugs 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 20
- 230000000968 intestinal effect Effects 0.000 abstract description 17
- 230000004083 survival effect Effects 0.000 abstract description 11
- 210000004211 gastric acid Anatomy 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000004071 biological effect Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 18
- 210000004051 gastric juice Anatomy 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229920000615 alginic acid Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229940072056 alginate Drugs 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 108010039918 Polylysine Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000007227 biological adhesion Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920005613 synthetic organic polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
- A23L3/46—Spray-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/31—Leuconostoc
- A23V2400/321—Mesenteroides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明提供了一种海藻酵素益生菌微胶囊及其制备方法,微胶囊包括微胶囊壁、微胶囊芯材和芯材载体,所述微胶囊壁由海藻酸钠、壳聚糖和氯化钙制备而成,所述微胶囊芯材由海藻酵素和益生菌制备而成,所述芯材载体为玉米淀粉。本发明的海藻酵素益生菌微胶囊可有效阻隔胃酸等对益生菌活菌数量和活性的影响,使海藻酵素和益生菌共同作用肠道微生态环境,发挥独特的生物学功效。该制备方法工艺简单,成本较低,易于储存运输,与其它益生菌产品相比,具有成膜性能好、稳定性能强、益生菌生存率高,缓释效能好等优点,适用于多种益生菌的包埋和可控释放,具有良好的应用前景。
Description
技术领域
本发明涉及一种海藻酵素益生菌微胶囊及其制备的方法,属于生物保健品技术领域。
背景技术
益生菌是指生存在人体胃肠道内活性的有益菌群,它们形成体内抵御疾病的第一道防线。益生菌制剂是指添加一定数量的对人和动植物有益菌,对宿主起有益健康作用的微生态制剂。目前国内使用的益生菌有 20 余种,主要有双歧杆菌、乳杆菌、酪酸梭菌、肠球菌等。临床与实验研究表明益生菌制剂能合成尼克酸、叶酸等多种维生素,促进蛋白质的消化吸收,影响肠道固有菌群的组成与功能、促进肠上皮细胞更新,并影响肠道免疫应答,对肠道菌群紊乱引起的临床疾病具有一定的治疗效果。
海藻酵素是海藻发酵生成的一些生理活性物质,包括维生素、氨基酸、多糖、益生菌,以及低聚糖等功能性成分。海藻通过发酵受到微生物酶的作用后功能性成分充分释放出来并发生小分子化而变得容易为人体吸收,而且经过发酵转化可增加海藻生物活性物质功效,降低其副作用,同时产生具有抗癌、降血脂、抗氧化、提高机体免疫功能的物质。海藻酵素的一些功能性物质通常以糖苷形态存在,因分子量大人体难以吸收,只有经过肠道微生物作用后,糖基被水解才易被人体吸收而发挥作用。
海藻酸钠是从褐藻类的海带或马尾藻中提取的天然高分子生物材料,又名褐藻酸钠、藻酸盐、褐藻胶等,能够和多数多价阳离子发生交联反应,形成凝胶或发生沉淀反应。海藻酸盐不仅具有良好的生物相容性和降解性,还具备优异的成凝胶性和成膜性,目前已被美国食品药品管理局批准使用。由于海藻酸盐是一种无毒、无刺激性、生物相容性良好的生物材料,因此人们制备基于海藻酸盐的生物微胶囊,将其作为植入人体的免疫隔离装置,在人体内发挥治疗作用。壳聚糖是一种价格便宜并且性质优良的天然高分子材料,其具有良好的生物相容性、可降解性和成膜性,这些性质使其成为制备微胶囊较好的壁材,同时壳聚糖作为壁材可以起到控制芯材释放的作用。
微胶囊是指利用天然合成的有机高分子材料,对分散的固体、液体、抑或是气体物质进行包裹,形成具有半透过性或密封囊膜的微小粒子。微胶囊技术广泛用于动物细胞培养、细胞和酶的固定化、生化药物控释及基因运载等生物医学领域。近些年,海藻酸钠-聚赖氨酸-海藻酸钠(alginate-polylysine-alginate,APA) 生物微胶囊研究最为广泛。但由于聚赖氨酸价格昂贵并且生物相容性差,限制了 APA 微胶囊的应用。后来发现壳聚糖与聚赖氨酸结构相似,可与海藻酸盐反应,形成凝胶结构,加强壁材对芯材的保护作用,在生物相容性和资源上有明显优势,随之替代了聚赖氨酸作为制备微胶囊的理想材料。壳聚糖和海藻酸钠为壁材所制备的海藻酸钠-壳聚糖微胶囊(alginate-chitisan-alginate ACA)具有较好的耐酸性、肠溶性和贮存稳定性等特点。
目前益生菌制剂作为功能食品具有卓越的益生功效,服用含有充足益生菌的制品有利于维持肠道平衡,提高机体免疫力等。但现在应用的益生菌产品存在不易控制和储存等特点,在进入人体消化道后,会受到低pH的胃酸、消化酶、胆汁酸等不利因素的影响导致益生菌进入人体肠道的活菌数显著减少,影响益生菌发挥其有益的生理功效。人体服用这样的益生菌产品,不能真正增强抵抗力并有效对抗有害菌。
发明内容
本发明的目的在于提供一种海藻酵素益生菌微胶囊及其制备方法,本发明的制备工艺简单,成本较低,易于储存运输,海藻酵素益生菌微胶囊具有成膜性能好、稳定性能强、益生菌生存率高,缓释效能好等优点,适用于多种益生菌的包埋和可控释放,具有良好的应用前景。
为此,本发明提供了一种海藻酵素益生菌微胶囊,包括微胶囊壁、微胶囊芯材和芯材载体,所述微胶囊壁由海藻酸钠、壳聚糖和氯化钙制备而成,所述微胶囊芯材由海藻酵素和益生菌制备而成,所述芯材载体为玉米淀粉。
优选的,所述微胶囊包括如下重量组份:海藻酸钠15-20份,壳聚糖2-4份,氯化钙10-15份、海藻酵素液15-25份、益生菌20-30份、玉米淀粉10-20份。
优选的,所述微胶囊的直径为4-8mm,所述微胶囊的包封率为73%-83%。
优选的,所述益生菌包含双歧杆菌、乳杆菌、酪酸梭菌、肠球菌和其他益生菌中的一种或其任意混合物。
优选的,所述双歧杆菌包括乳双歧杆菌、两歧双歧杆菌、青春双歧杆菌和婴儿双歧杆菌中的至少一种,所述乳杆菌包括嗜酸乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、植物乳杆菌、保加利亚乳杆菌、瑞士乳杆菌、干酪乳杆菌或副干酪乳杆菌中的至少一种,所述其他益生菌包括嗜热链球菌、肠膜明串珠菌中的至少一种。
优选的,所述海藻酵素为褐藻酵素、红藻酵素和绿藻酵素中的一种或其任意混合物;
所述褐藻酵素由褐藻制成,所述褐藻包括海带、昆布、裙带菜或羊栖菜中的至少一种;所述红藻酵素由红藻制成,所述红藻包括紫菜、石花菜、龙须菜、角叉菜或麒麟菜中的至少一种;所述绿藻酵素由绿藻制成,所述绿藻包括石莼或浒苔中的至少一种。
本发明还提供了所述的海藻酵素益生菌微胶囊的制备方法,所述方法包括:(1)制备活化益生菌菌种:将一种或多种益生菌菌粉接种至已灭菌冷却的MRS液体培养基中,在37℃恒温培养进入稳定期后,4000r/min离心并用生理盐水洗涤,收集浓缩菌液;(2)制备海藻酵素液:将新鲜海藻原料切碎浸泡30-50min,加入复合酶于35℃酶解,经巴氏灭菌后接种30-50℃发酵 3-6天后,通过固液分离得到海藻酵素液;(3)配制芯材混合液:将步骤(1)浓缩菌液和步骤(2)海藻酵素液混合,得到海藻酵素益生菌混合液,将海藻酵素益生菌混合液与1-2g玉米淀粉搅拌均匀,加入到20-40ml海藻酸钠溶液中混合均匀得到芯材混合液,取10-20mL芯材混合液备用;(4)配制壳聚糖氯化钙溶液:以1%冰乙酸溶解并稀释氯化钙溶液,取40-60mL稀释后的氯化钙溶液备用;取40-60mL壳聚糖溶液倒入上述稀释后的氯化钙溶液中进行固化0.5-1小时,得到壳聚糖氯化钙溶液;(5)制备缓释微胶囊:将步骤(3)制备的芯材混合液置于注射容器中,滴入步骤(4)壳聚糖氯化钙溶液中进行成膜反应形成凝胶,用磁力搅拌器 200 r/min转速搅拌,最后置于低温喷雾干燥机中干燥得微胶囊。
优选的,所述步骤(1)中,MRS液体培养基为:牛肉膏10.0g,蛋白胨10.0g,酵母膏5.0 g,三水合乙酸钠 5.0g,葡萄糖 20.0g,柠檬酸二氨 2.0g,MgSO4·7 H2O 0.58g,K2HPO4 2.0 g,MnSO4·H2O 0.2g,吐温 80 1.0mL,蒸馏水 1000mL,pH6.5,121℃条件下灭菌20min。
优选的,所述步骤(4)中,氯化钙溶液质量分数为1.5%-2.5%,壳聚糖溶液质量分数为0.3%-0.5%,并将调节pH 值至5-6。
优选的,所述步骤(5)中,注射溶器针头内径0.5mm;微胶囊填料过程中使用脉冲式微量定量吹氮技术方法,在标准大气压下,混合液经注射器针头流出时被同方向的氮气将液滴吹落,滴入氯化钙溶液中与钙离子交联进行成膜反应交联形成稳定凝胶;微胶囊干燥过程使用恒温真空干燥机,干燥温度为30℃-40℃,干燥时间为20h-24h。
与现有技术相比,本发明的优点和积极效果是:本发明提供了一种海藻酵素益生菌微胶囊及其制备方法,微胶囊包括微胶囊壁、微胶囊芯材和芯材载体,所述微胶囊壁由海藻酸钠、壳聚糖和氯化钙制备而成,所述微胶囊芯材由海藻酵素和益生菌制备而成,所述芯材载体为玉米淀粉。本发明的制备工艺简化、产品纯度和溶解度较高,明显增强了海藻酵素和益生菌对机体的生物学功效。本发明建立的将活化的益生菌菌种与海藻酵素粉混合,再与玉米淀粉搅拌均匀,加入海藻酸钠溶液后制成混合液,滴入到壳聚糖-氯化钙溶液中进行成膜反应,最后得到海藻酵素益生菌缓释微胶囊的技术方法,该制备方法简便迅速,成囊速度快,工艺参数易于操作控制,可提高制备效率,增强芯材功效,且微囊化物质不容易在制备过程中流失从而增加生产效益。
(1)海藻酸钠、壳聚糖、氯化钙作为微胶囊壁材,具有抗酸和肠溶性的特点和良好的生物黏附特性,可有效阻隔消化酶和胃酸等对益生菌活菌数量和活性的影响,对益生菌起到一定的保护效果,增强其对胃酸的耐受性,保证到达肠道的菌群活性,提高穿过胃部酸性环境抵达肠道的海藻酵素和益生菌的比例,从而增强其生物学功效;同时微胶囊芯材与外界环境隔离被封闭包埋在微胶囊壁内,可提高其在环境中的稳定性,易于储存和运输。
(2)将海藻酵素与益生菌混合作为微胶囊芯材包埋,海藻酵素穿过胃液的强酸环境进入肠道后才被释放,使其含有的活性物质充分释放发挥功效,同时对于益生菌的活化吸收也具有一定的促进作用。海藻酵素和益生菌相互促进共同作用肠道微生态环境,补充有益菌的数量和丰度,调节肠道菌群紊乱,刺激机体免疫防御机制,有效发挥各自独特的药理作用。
(3)玉米淀粉作为芯材载体,由于其具有结构紧密和不易酶解等特点,有利于芯材成分海藻酵素和益生菌在肠道缓慢释放,延长它们在机体内的作用时间,增强对肠道微生物屏障修复和保护的效果,同时对芯材的包埋率也有一定的提高作用。
(4)微胶囊填料过程中使用脉冲式微量定量吹氮技术,与金属离子钙交联形成稳定胶球, 而不是传统的利用重力自动流入,更容易控制微胶囊大小与质量。同时此方法可调节气流的速度和针头孔径,从而有效控制微囊的直径。
(5)本发明进行恒温干燥处理微胶囊,可延长海藻酵素和益生菌的贮存时间,避免现有冷冻干燥致使菌体失活的缺点。
具体实施方式
以下对本发明的具体实施方式进行详细说明,应当理解的是,此处所描述的具体实施方式仅用于说明和解释本发明,并不用于限制本发明。
本发明的海藻酵素益生菌微胶囊包括微胶囊壁、微胶囊芯材和芯材载体,所述微胶囊壁由海藻酸钠、壳聚糖和氯化钙制备而成,所述微胶囊芯材由海藻酵素和益生菌制备而成,所述芯材载体为玉米淀粉。
本发明的海藻酵素益生菌微胶囊包括微胶囊壁和包埋于微胶囊壁内的微胶囊芯材,微胶囊壁由外至内包括壳聚糖沉淀层、海藻酸钠-壳聚糖络合层、海藻酸钙凝胶层,微胶囊芯材为液态海藻酵素益生菌。本发明的海藻酵素益生菌微胶囊可有效阻隔胃酸等对益生菌活菌数量和活性的影响,使海藻酵素和益生菌共同作用肠道微生态环境,发挥独特的生物学功效。本发明的制备工艺简单,成本较低,易于储存运输,与其它益生菌产品相比,具有成膜性能好、稳定性能强、益生菌生存率高,缓释效能好等优点,适用于多种益生菌的包埋和可控释放,具有良好的应用前景。
具体的:(1)海藻酸钠、壳聚糖、氯化钙作为微胶囊壁材,具有抗酸和肠溶性的特点和良好的生物黏附特性,可有效阻隔消化酶和胃酸等对益生菌活菌数量和活性的影响,保证到达肠道的菌群活性,提高穿过胃部酸性环境抵达肠道的海藻酵素和益生菌比例,从而增强其生物学功效;同时微胶囊芯材被封闭包埋在微胶囊壁内、与外界环境隔离,提高其在环境中的稳定性,易于储存和运输。将海藻酸钠-氯化钙作为微胶囊的包埋壁材,可对益生菌起到有效的保护效果,增强其对胃酸的耐受性。(2)将海藻酵素与益生菌混合作为微胶囊芯材包埋,海藻酵素穿过胃液的强酸环境进入肠道后才被释放,使其含有的活性物质充分释放发挥功效,同时对于益生菌的活化吸收也具有一定的促进作用。海藻酵素和益生菌相互促进共同作用肠道微生态环境,补充有益菌的数量和丰度,调节肠道菌群紊乱,刺激机体免疫防御机制,有效发挥各自独特的药理作用。(3)玉米淀粉作为芯材载体,由于其具有结构紧密和不易酶解等特点,有利于芯材成分海藻酵素和益生菌在肠道缓慢释放,延长它们在机体内的作用时间,增强对肠道微生物屏障修复和保护的效果,同时对芯材的包埋率也有一定的提高作用。
所述微胶囊包括如下重量组份:海藻酸钠15-20份,壳聚糖2-4份,氯化钙10-15份、海藻酵素液15-25份、益生菌20-30份、玉米淀粉10-20份。本发明的海藻酸钠为15-20份,有利于调整体系合适的粘度,避免制作的微胶囊拖尾变形;壳聚糖为2-4份,可使海藻酸钠-壳聚糖的聚电解质半透膜厚度与疏密程度适中;氯化钙为10-15份,使所形成的微胶囊粒径与囊壁厚度达到要求的标准;海藻酸钠、壳聚糖和氯化钙共同构成微胶囊的壁材,三者合适的份数比例使微胶囊达到最佳的成囊效果。海藻酵素液与益生菌作为芯材,选择其合适的份数比例可在节约产品成本的同时达到最佳的包封率。另外海藻酵素液与益生菌的份数比例也有助于提高海藻酵素的活性成分和益生菌的存活率。玉米淀粉合适的份数比例使微胶囊结构紧密,不易酶解,具有更好的缓释性能。
所述微胶囊的直径为4-8mm,所述微胶囊的包封率为73%-83%。微胶囊合适的微粒直径范围可使微囊化物质不容易在制备过程中丢失,服用后芯材的功能性成分得以充分释放出来容易为人体吸收,从而达到理想的生物学功效,而且在制备工艺中可达到最佳的包封率,可控缓释效果最好。
所述益生菌包含双歧杆菌、乳杆菌、酪酸梭菌、肠球菌和其他益生菌中的一种或其任意混合物。这些益生菌均为肠道微生态的有益菌群,其数量、丰度和构成比的变化与肠道菌群紊乱导致的疾病密切相关,所以根据不同目的选择合适菌群作为芯材制作的微胶囊,具有靶向预防和治疗某种菌群失调所致胃肠道等疾病的功效。
所述双歧杆菌包括乳双歧杆菌、两歧双歧杆菌、青春双歧杆菌和婴儿双歧杆菌中的至少一种,所述乳杆菌包括嗜酸乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、植物乳杆菌、保加利亚乳杆菌、瑞士乳杆菌、干酪乳杆菌或副干酪乳杆菌中的至少一种,所述其他益生菌包括嗜热链球菌、肠膜明串珠菌中的至少一种。
所述海藻酵素为褐藻酵素、红藻酵素和绿藻酵素中的一种或其任意混合物;所述褐藻酵素由褐藻制成,所述褐藻包括海带、昆布、裙带菜或羊栖菜中的至少一种;所述红藻酵素由红藻制成,所述红藻包括紫菜、石花菜、龙须菜、角叉菜或麒麟菜中的至少一种;所述绿藻酵素由绿藻制成,所述绿藻包括石莼或浒苔中的至少一种。褐藻、红藻和绿藻是大型藻类,也是制造海藻酵素的最主要原料。选择这样的藻类有利于产生高活性的蛋白酶、淀粉酶等酵素成分和海藻活性寡糖等特定的生理活性物质,形成高品质易消化的海藻酵素。作为微胶囊的重要芯材,此种原料制作的海藻酵素可提高益生菌的存活率,有利于酵素和益生菌协同发挥活性作用,产生最佳的生物学功效。
本发明的海藻酵素益生菌微胶囊的制备方法包括:
(1)制备活化益生菌菌种:将一种或多种益生菌菌粉接种至已灭菌冷却的MRS液体培养基中,在 37℃恒温培养进入稳定期后,4000r/min离心并用生理盐水洗涤,收集浓缩菌液;MRS液体培养基为:牛肉膏10.0g,蛋白胨10.0g,酵母膏5.0 g,三水合乙酸钠 5.0g,葡萄糖20.0g,柠檬酸二氨 2.0g,MgSO4·7 H2O 0.58g,K2HPO4 2.0 g,MnSO4·H2O 0.2g,吐温 801.0mL,蒸馏水 1000mL,pH6.5,121℃条件下灭菌20min。
(2)制备海藻酵素液:将新鲜海藻原料切碎浸泡30-50min,加入复合酶于35℃酶解,经巴氏灭菌后接种30-50℃发酵 3-6天后,通过固液分离得到海藻酵素液。
(3)配制芯材混合液:将步骤(1)浓缩菌液和步骤(2)海藻酵素液混合,得到海藻酵素益生菌混合液,将海藻酵素益生菌混合液与1-2g玉米淀粉搅拌均匀,加入到20-40ml海藻酸钠溶液中混合均匀得到芯材混合液,取10-20mL芯材混合液备用;
(4)配制壳聚糖氯化钙溶液:以1%冰乙酸溶解并稀释质量分数为1.5%-2.5%的氯化钙溶液,取40-60mL稀释后的氯化钙溶液备用;取40-60mL、质量分数为0.3%-0.5%的壳聚糖溶液、调节其pH 值至5-6,将壳聚糖溶液倒入上述稀释后的氯化钙溶液中进行固化0.5-1小时,得到壳聚糖氯化钙溶液。
(5)制备缓释微胶囊:将步骤(3)制备的芯材混合液置于注射容器中,滴入步骤(4)壳聚糖氯化钙溶液中进行成膜反应形成凝胶,用磁力搅拌器 200 r/min转速搅拌,最后置于低温喷雾干燥机中干燥得微胶囊;注射溶器针头内径0.5mm;微胶囊填料过程中使用脉冲式微量定量吹氮技术方法,在标准大气压下,混合液经注射器针头流出时被同方向的氮气将液滴吹落,滴入氯化钙溶液中与钙离子交联进行成膜反应交联形成稳定凝胶;微胶囊干燥过程使用恒温真空干燥机,干燥温度为30℃-40℃,干燥时间为20h-24h。
实施例1
(1)制备活化益生菌菌种:在无菌条件下操作,将罗伊氏乳杆菌菌粉接种至已灭菌冷却的MRS液体培养基中,将容器口密封,在 37℃恒温静置培养20小时后菌体进入稳定期,4000 r/min离心10 min,用0.9g/100mL无菌生理盐水洗涤2次,收集浓缩菌液。
(2)制备海藻酵素液:将新鲜裙带菜切碎后放入水中浸泡30min,加入复合酶于35℃酶解2h,经巴氏灭菌后接种食用级枯草芽孢杆菌与植物乳杆菌置于发酵罐进行发酵,40℃发酵4天,通过固液分离得到液体裙带菜酵素。
(3)配制芯材混合液:将步骤(1)罗伊氏乳杆菌浓缩菌液和步骤(2)液体裙带菜酵素各取20mL混合均匀,再添加1g玉米淀粉搅拌后,加入到灭菌且质量分数2.5%的海藻酸钠溶液30mL中混合均匀,得到芯材混合液,取15mL芯材混合液备用。
(4)配制壳聚糖氯化钙溶液:以1%冰乙酸溶解并稀释质量分数2.0%的氯化钙溶液,取稀释后的氯化钙溶液50mL备用;称取壳聚糖制备质量分数0.3%的壳聚糖溶液,调节pH 值至5.5,取50mL壳聚糖溶液到上述50mL氯化钙溶液中进行固化0.5h,得到壳聚糖氯化钙溶液。
(5)制备缓释微胶囊:将步骤(3)芯材混合液置于注射容器中,在填料时采用脉冲式微量定量吹氮技术,在一定气压下,芯材混合液经注射器针头流出时被同方向的气体将液滴吹落,滴入步骤(4)的壳聚糖氯化钙溶液中进行成膜反应形成凝胶,用磁力搅拌器 200r/min转速搅拌,最后置于37℃恒温干燥20h,得平均直径4.4mm的微胶囊,包封率最终达到73.7%。
将上述实施例获得的微胶囊进行应用性测试:
1、微胶囊人工胃液耐受试验:胶囊中的罗伊氏乳杆菌在人工胃液中的存活率虽然随着处理时间的延长逐渐降低,但在pH为1.5的人工胃液中处理3h后海藻酵素微胶囊中罗伊氏乳杆菌的菌体存活率仍可达到80%左右。而对于没有经过微胶囊化的罗伊氏乳杆菌,在人工胃液中处理相同时间后,菌体存活率仅有37.5%。
2、微胶囊肠液溶解性试验:将经过人工胃液处理3h后未溶解的微胶囊转移至人工肠液中处理2h,每隔20min测定透光率来分析罗伊氏乳杆菌在人工肠液中的释放情况,结果发现微胶囊在人工肠液中处理100min后基本完全崩解。
实施例2
(1)活化益生菌菌种:在无菌条件下操作,将植物乳杆菌和乳双歧杆菌的菌粉接种至已灭菌冷却的MRS液体培养基中,将容器口密封,在 37℃恒温培养静置至18小时菌体进入稳定期后,置入离心机 4000 r/min离心10 min,用0.9g/100mL无菌生理盐水洗涤3 次,收集浓缩菌液。
(2)制备海藻酵素液:将新鲜浒苔切碎后放入水中浸泡30min,加入复合酶于35℃酶解2h,经巴氏灭菌后接种食用级枯草芽孢杆菌置于发酵罐45℃进行发酵4天,通过固液分离得到液体浒苔酵素。
(3)配制芯材混合液:将步骤(1)植物乳杆菌和乳双歧杆菌浓缩菌液、步骤(2)液体浒苔酵素各取30mL混合,再与1.5g玉米淀粉搅拌均匀,加入到灭菌且质量分数2.8%海藻酸钠溶液40mL中混合均匀,得到芯材混合液,取20mL芯材混合液备用。
(4)配制壳聚糖氯化钙溶液:以1%冰乙酸溶解配制质量分数2.5%氯化钙溶液,取氯化钙溶液60mL备用;称取适量的壳聚糖制备质量分数0.5%壳聚糖溶液,调节pH 值至5.8,取40mL壳聚糖溶液到上述备用的氯化钙溶液中进行固化1h,得到壳聚糖氯化钙溶液。
(5)制备缓释微胶囊:将步骤(3)芯材混合液置于注射容器中,在填料时采用脉冲式微量定量吹氮技术,在一定气压下,芯材混合液经注射器针头流出时被同方向的气体将液滴吹落,滴入步骤(4)的壳聚糖氯化钙溶液中进行成膜反应形成凝胶,用磁力搅拌器 200r/min转速搅拌,最后置于40℃恒温干燥22h,形成的微胶囊平均直径大约7.5mm,该方案的包封率为79.3%。
将上述实施例获得的微胶囊进行应用性测试:
1、微胶囊人工胃液耐受试验:胶囊中的植物乳杆菌和乳双歧杆菌在人工胃液中的存活率虽然随着处理时间的延长逐渐降低,在pH1.5的人工胃液中处理3h后海藻酵素微胶囊中罗伊氏乳杆菌的菌体存活率仍可达到72%左右。而对于没有经过微胶囊化的植物乳杆菌和乳双歧杆菌,在人工胃液中处理相同时间后,菌体存活率仅有35.6%。
2、微胶囊肠液溶解性试验:将经过人工胃液处理3h后未溶解的微胶囊转移至人工肠液中处理2h,每隔20min测定透光率来分析植物乳杆菌和乳双歧杆菌在人工肠液中的释放情况,结果发现微胶囊在人工肠液中处理120min后基本崩解完全。
以上所述,仅是本发明的较佳实施例而已,并非是对本发明作其它形式的限制,任何熟悉本专业的技术人员可能利用上述揭示的技术内容加以变更或改型为等同变化的等效实施例。但是凡是未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与改型,仍属于本发明技术方案的保护范围。
Claims (10)
1.一种海藻酵素益生菌微胶囊,其特征在于,
包括微胶囊壁、微胶囊芯材和芯材载体,
所述微胶囊壁由海藻酸钠、壳聚糖和氯化钙制备而成,
所述微胶囊芯材由海藻酵素和益生菌制备而成,
所述芯材载体为玉米淀粉。
2.根据权利要求1所述的海藻酵素益生菌微胶囊,其特征在于,
所述微胶囊包括如下重量组份:海藻酸钠15-20份,壳聚糖2-4份,氯化钙10-15份、海藻酵素液15-25份、益生菌20-30份、玉米淀粉10-20份。
3.根据权利要求1所述的海藻酵素益生菌微胶囊,其特征在于,
所述微胶囊的直径为4-8mm,所述微胶囊的包封率为73%-83%。
4.根据权利要求1所述的海藻酵素益生菌微胶囊,其特征在于,
所述益生菌包含双歧杆菌、乳杆菌、酪酸梭菌、肠球菌和其他益生菌中的一种或其任意混合物。
5.根据权利要求4所述的海藻酵素益生菌微胶囊,其特征在于,
所述双歧杆菌包括乳双歧杆菌、两歧双歧杆菌、青春双歧杆菌和婴儿双歧杆菌中的至少一种,所述乳杆菌包括嗜酸乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、植物乳杆菌、保加利亚乳杆菌、瑞士乳杆菌、干酪乳杆菌或副干酪乳杆菌中的至少一种,
所述其他益生菌包括嗜热链球菌、肠膜明串珠菌中的至少一种。
6.根据权利要求1所述的海藻酵素益生菌微胶囊,其特征在于,
所述海藻酵素为褐藻酵素、红藻酵素和绿藻酵素中的一种或其任意混合物;
所述褐藻酵素由褐藻制成,所述褐藻包括海带、昆布、裙带菜或羊栖菜中的至少一种;
所述红藻酵素由红藻制成,所述红藻包括紫菜、石花菜、龙须菜、角叉菜或麒麟菜中的至少一种;
所述绿藻酵素由绿藻制成,所述绿藻包括石莼或浒苔中的至少一种。
7.根据权利要求1-6中任一项所述的海藻酵素益生菌微胶囊的制备方法,其特征在于,
所述方法包括:
(1)制备活化益生菌菌种:将一种或多种益生菌菌粉接种至已灭菌冷却的MRS液体培养基中,在 37℃恒温培养进入稳定期后,4000r/min离心并用生理盐水洗涤,收集浓缩菌液;
(2)制备海藻酵素液:将新鲜海藻原料切碎浸泡30-50min,加入复合酶于35℃酶解,经巴氏灭菌后接种30-50℃发酵 3-6天后,通过固液分离得到海藻酵素液;
(3)配制芯材混合液:将步骤(1)浓缩菌液和步骤(2)海藻酵素液混合,得到海藻酵素益生菌混合液,将海藻酵素益生菌混合液与1-2g玉米淀粉搅拌均匀,加入到20-40ml海藻酸钠溶液中混合均匀得到芯材混合液,取10-20mL芯材混合液备用;
(4)配制壳聚糖氯化钙溶液:以1%冰乙酸溶解并稀释氯化钙溶液,取40-60mL稀释后的氯化钙溶液备用;取40-60mL壳聚糖溶液倒入上述稀释后的氯化钙溶液中进行固化0.5-1小时,得到壳聚糖氯化钙溶液;
(5)制备缓释微胶囊:将步骤(3)制备的芯材混合液置于注射容器中,滴入步骤(4)壳聚糖氯化钙溶液中进行成膜反应形成凝胶,用磁力搅拌器 200 r/min转速搅拌,最后置于恒温真空干燥机中干燥得微胶囊。
8.根据权利要求7所述的海藻酵素益生菌微胶囊的制备方法,其特征在于,
所述步骤(1)中,MRS液体培养基为:牛肉膏10.0g,蛋白胨10.0g,酵母膏5.0 g,三水合乙酸钠 5.0g,葡萄糖 20.0g,柠檬酸二氨 2.0g,MgSO4·7 H2O0.58g,K2HPO4 2.0 g,MnSO4·H2O 0.2g,吐温 80 1.0mL,蒸馏水 1000mL,pH6.5,121℃条件下灭菌20min。
9.根据权利要求7所述的海藻酵素益生菌微胶囊的制备方法,其特征在于,
所述步骤(4)中,氯化钙溶液质量分数为1.5%-2.5%,壳聚糖溶液质量分数为0.3%-0.5%,并将调节pH 值至5-6。
10.根据权利要求7所述的海藻酵素益生菌微胶囊的制备方法,其特征在于,
所述步骤(5)中,注射溶器针头内径0.5mm;
微胶囊填料过程中使用脉冲式微量定量吹氮技术方法,在标准大气压下,混合液经注射器针头流出时被同方向的氮气将液滴吹落,滴入氯化钙溶液中与钙离子交联进行成膜反应交联形成稳定凝胶;
微胶囊干燥过程使用恒温真空干燥机,干燥温度为30℃-40℃,干燥时间为20h-24h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010393045.5A CN111588038A (zh) | 2020-05-11 | 2020-05-11 | 一种海藻酵素益生菌微胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010393045.5A CN111588038A (zh) | 2020-05-11 | 2020-05-11 | 一种海藻酵素益生菌微胶囊及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111588038A true CN111588038A (zh) | 2020-08-28 |
Family
ID=72183621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010393045.5A Pending CN111588038A (zh) | 2020-05-11 | 2020-05-11 | 一种海藻酵素益生菌微胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111588038A (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112544981A (zh) * | 2020-12-28 | 2021-03-26 | 河南省商业科学研究所有限责任公司 | 一种沙棘益生菌微胶囊的制备方法及其制备的沙棘益生菌微胶囊产品 |
CN113230284A (zh) * | 2021-05-14 | 2021-08-10 | 青岛海洋生物医药研究院股份有限公司 | 一种基于多维交联的合生素微囊化制剂及其制备方法和应用 |
CN113274369A (zh) * | 2021-04-29 | 2021-08-20 | 暨南大学 | 一种结肠靶向的口服益生菌微囊及其制备方法与应用 |
CN113499325A (zh) * | 2021-07-08 | 2021-10-15 | 成都邦家乐君生物科技有限公司 | 一种用于益生菌活性保护的生物质基包封材料及包封方法 |
CN113575964A (zh) * | 2021-08-05 | 2021-11-02 | 黄辉 | 一种抗氧化和抗衰老的益生菌组合物及其制备方法 |
CN113995068A (zh) * | 2021-09-24 | 2022-02-01 | 国投中鲁果汁股份有限公司 | 苹果海盐发酵饮料及其制备方法 |
CN114146120A (zh) * | 2022-02-08 | 2022-03-08 | 首都医科大学附属北京潞河医院 | 一种预防及治疗萎缩性胃炎的组合物微胶囊及其制备方法 |
CN114223795A (zh) * | 2021-12-21 | 2022-03-25 | 西南科技大学 | 一种仔猪用益生菌饲料的制备方法 |
CN114304616A (zh) * | 2021-12-28 | 2022-04-12 | 广州市沐家健康产业有限公司 | 一种酵素组合物及其制备方法 |
CN115462493A (zh) * | 2022-09-27 | 2022-12-13 | 青岛啤酒股份有限公司 | 基于植物多肽封装掩味的复合纳米颗粒及所得饮品 |
CN116784452A (zh) * | 2023-05-04 | 2023-09-22 | 河北同福健康产业有限公司 | 一种老面馒头复合发酵菌及其制备方法 |
TWI819509B (zh) * | 2022-03-07 | 2023-10-21 | 健茂生物科技股份有限公司 | 海葡萄發酵液的製造方法 |
CN117297100A (zh) * | 2023-11-28 | 2023-12-29 | 南昌大学 | 多流体同轴喷雾制备的益生菌微胶囊及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1969889A (zh) * | 2006-12-04 | 2007-05-30 | 济南赛拜斯生物工程有限公司 | 肠溶性多层包被益生菌微胶囊及其制备方法 |
CN107267493A (zh) * | 2017-06-01 | 2017-10-20 | En科技有限公司 | 一种酵素水凝胶颗粒及其制备方法 |
CN109007807A (zh) * | 2018-08-13 | 2018-12-18 | 上海应用技术大学 | 一种微胶囊水果酵素粉及其制备方法 |
CN110916177A (zh) * | 2019-12-20 | 2020-03-27 | 中国科学院烟台海岸带研究所 | 一种通过酶酵耦合技术制备的海带酵素方法 |
-
2020
- 2020-05-11 CN CN202010393045.5A patent/CN111588038A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1969889A (zh) * | 2006-12-04 | 2007-05-30 | 济南赛拜斯生物工程有限公司 | 肠溶性多层包被益生菌微胶囊及其制备方法 |
CN107267493A (zh) * | 2017-06-01 | 2017-10-20 | En科技有限公司 | 一种酵素水凝胶颗粒及其制备方法 |
CN109007807A (zh) * | 2018-08-13 | 2018-12-18 | 上海应用技术大学 | 一种微胶囊水果酵素粉及其制备方法 |
CN110916177A (zh) * | 2019-12-20 | 2020-03-27 | 中国科学院烟台海岸带研究所 | 一种通过酶酵耦合技术制备的海带酵素方法 |
Non-Patent Citations (1)
Title |
---|
卢晓霆等: "玉米多孔淀粉-海藻酸钠-壳聚糖-葡萄多酚缓释微胶囊的制备及表征", 《中草药》 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112544981A (zh) * | 2020-12-28 | 2021-03-26 | 河南省商业科学研究所有限责任公司 | 一种沙棘益生菌微胶囊的制备方法及其制备的沙棘益生菌微胶囊产品 |
CN113274369A (zh) * | 2021-04-29 | 2021-08-20 | 暨南大学 | 一种结肠靶向的口服益生菌微囊及其制备方法与应用 |
CN113230284A (zh) * | 2021-05-14 | 2021-08-10 | 青岛海洋生物医药研究院股份有限公司 | 一种基于多维交联的合生素微囊化制剂及其制备方法和应用 |
CN113499325A (zh) * | 2021-07-08 | 2021-10-15 | 成都邦家乐君生物科技有限公司 | 一种用于益生菌活性保护的生物质基包封材料及包封方法 |
CN113575964A (zh) * | 2021-08-05 | 2021-11-02 | 黄辉 | 一种抗氧化和抗衰老的益生菌组合物及其制备方法 |
CN113995068A (zh) * | 2021-09-24 | 2022-02-01 | 国投中鲁果汁股份有限公司 | 苹果海盐发酵饮料及其制备方法 |
CN114223795B (zh) * | 2021-12-21 | 2023-05-23 | 西南科技大学 | 一种仔猪用益生菌饲料的制备方法 |
CN114223795A (zh) * | 2021-12-21 | 2022-03-25 | 西南科技大学 | 一种仔猪用益生菌饲料的制备方法 |
CN114304616A (zh) * | 2021-12-28 | 2022-04-12 | 广州市沐家健康产业有限公司 | 一种酵素组合物及其制备方法 |
CN114146120A (zh) * | 2022-02-08 | 2022-03-08 | 首都医科大学附属北京潞河医院 | 一种预防及治疗萎缩性胃炎的组合物微胶囊及其制备方法 |
TWI819509B (zh) * | 2022-03-07 | 2023-10-21 | 健茂生物科技股份有限公司 | 海葡萄發酵液的製造方法 |
CN115462493A (zh) * | 2022-09-27 | 2022-12-13 | 青岛啤酒股份有限公司 | 基于植物多肽封装掩味的复合纳米颗粒及所得饮品 |
CN115462493B (zh) * | 2022-09-27 | 2023-09-05 | 青岛啤酒股份有限公司 | 基于植物多肽封装掩味的复合纳米颗粒及所得饮品 |
CN116784452A (zh) * | 2023-05-04 | 2023-09-22 | 河北同福健康产业有限公司 | 一种老面馒头复合发酵菌及其制备方法 |
CN117297100A (zh) * | 2023-11-28 | 2023-12-29 | 南昌大学 | 多流体同轴喷雾制备的益生菌微胶囊及其制备方法和应用 |
CN117297100B (zh) * | 2023-11-28 | 2024-04-26 | 南昌大学 | 多流体同轴喷雾制备的益生菌微胶囊及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111588038A (zh) | 一种海藻酵素益生菌微胶囊及其制备方法 | |
CN109619593B (zh) | 一种益生菌双层微胶囊及其制备方法 | |
CN108618151B (zh) | 一种保持菌种活性的益生菌微胶囊及其制备方法 | |
Islam et al. | Microencapsulation of live probiotic bacteria | |
CN109674061A (zh) | 一种双层微囊化的益生元、益生菌组合物及其制备方法 | |
CN112544978B (zh) | 一种可在肠道定点释放的微胶囊包埋的益生菌及其制备方法 | |
CN1843385A (zh) | 肠道微生态制剂及其制备方法 | |
CN114287632A (zh) | 一种菊粉益生菌微胶囊的制备方法 | |
CN111602810A (zh) | 一种益生菌黄皮微胶囊及其制备方法和应用 | |
EP1514553B1 (en) | Lactic acid bacteria powder double-coated using protein and polysaccharide and method preparing the same and a dosage form thereof | |
CN107647251A (zh) | 一种复合食用菌营养咀嚼片的制备方法 | |
CN112890204A (zh) | 一种利用葡萄籽提取物作为益生元的微胶囊及其制备方法 | |
CN115944665A (zh) | 一种改善肠道菌群平衡的益生菌剂及其制备方法和应用 | |
KR101707551B1 (ko) | 유산균 생균 제제를 함유한 초콜릿의 제조 방법 | |
CN102077932A (zh) | 一种富含高活性肠道益生菌营养果冻的制作方法 | |
CN105230782A (zh) | 一种发菜酸奶的制备方法 | |
CN108095077B (zh) | 一种利用益生菌制备竹笋酵素粉的方法 | |
CN111920048A (zh) | 一种含有玫瑰发酵液的胶囊及其制备方法 | |
CN111345473A (zh) | 一种含卵黄抗体IgY的益生菌组合物及应用制剂 | |
WO2020107580A1 (zh) | 以阿拉伯木聚糖-海藻酸钠为壁材的益生菌微胶囊及制法 | |
CN100402042C (zh) | 增强肾功能的组合物及方法 | |
KR100473391B1 (ko) | 생리적 특성이 증진된 유산균 분말 및 이의 제조 방법 | |
CN102919669B (zh) | 以谷物粉为包埋材料制作固定化益生菌的方法 | |
KR100493354B1 (ko) | 레반 및 알기네이트 비드로 코팅되어 생존율이 향상된유산균 분말 및 그의 제조방법 | |
CN112006285A (zh) | 一种靶向定植的益生菌粉及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200828 |
|
RJ01 | Rejection of invention patent application after publication |